DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Up 297.0% in October

DBV Technologies S.A. (NASDAQ:DBVT) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,330,000 shares, an increase of 297.0% from the October 15th total of 335,000 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily volume of 655,300 shares, the days-to-cover ratio is presently 2.0 days.

Analyst Ratings Changes

DBVT has been the subject of several recent research reports. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright boosted their price target on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. Finally, StockNews.com initiated coverage on DBV Technologies in a report on Wednesday, November 6th. They issued a “hold” rating for the company.

DBV Technologies Trading Down 2.2 %

Shares of DBVT stock traded down $0.01 during trading hours on Wednesday, hitting $0.62. 72,309 shares of the company’s stock were exchanged, compared to its average volume of 231,567. The firm has a 50 day moving average of $0.74 and a two-hundred day moving average of $0.90. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.14.

Shares of DBV Technologies are scheduled to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.